Lastly, Δ1-9-G129R-hPRL treatment prevented early stages of prostate carcinogenesis by inhibiting STAT5 phosphorylation, proliferation, abnormal basal-cell pattern and grade of intraepithelial prostate neoplasia suggesting the application of PRLR-based therapies in prostate cancer (68). The gene discussed is PRLR; the disease is prostatitis.